Hamed Rahmani Youshanlouei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hamed Rahmani Youshanlouei has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Adam DuVall
Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, USA
11 shared publications - Anand Ashwin Patel
Section of Hematology/Oncology, Department of Medicine University of Chicago Chicago Illinois USA
11 shared publications - Arjun Dhar
University of Chicago 1 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois
11 shared publications - Caner Saygin
Section of Hematology/Oncology, University of Chicago, Chicago, Illinois
11 shared publications - Diren Arda Karaoglu
Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey
11 shared publications - Michael William Drazer
University of Chicago 1 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois
11 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia
- 8 September 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessMCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Gene network maps showing fold-changes in the genes involved in down-regulated (A) or up-regulated (B) pathways in T-ALL primary cells treated with ziftomenib.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Gene network maps showing fold-changes in the genes involved in down-regulated (A) or up-regulated (B) pathways in T-ALL primary cells treated with ziftomenib.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Dose-response curves represent ziftomenib sensitivities of HOXA-low vs HOXA-high T-ALL cell lines. (B) Heatmap showing RNA expression of HOXB, HOXC, HOXD genes in T-ALL patient samples. (C) Splenectomy specimens of NSG mice engrafted with KARPAS-45 cells and treated with vehicle vs ziftomenib at two different dose levels for 4 weeks. (D,E) Tumor burden in bone marrow and spleen of treated mice. (F) Histopathologic analysis of organs harvested from NSG mice treated with vehicle or ziftomenib at two different dose levels showed increased leukemic cell burden (arrows) in livers of vehicle-treated mice but no microscopic evidence of toxicity to liver, heart, kidney or guts.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Dose-response curves represent ziftomenib sensitivities of HOXA-low vs HOXA-high T-ALL cell lines. (B) Heatmap showing RNA expression of HOXB, HOXC, HOXD genes in T-ALL patient samples. (C) Splenectomy specimens of NSG mice engrafted with KARPAS-45 cells and treated with vehicle vs ziftomenib at two different dose levels for 4 weeks. (D,E) Tumor burden in bone marrow and spleen of treated mice. (F) Histopathologic analysis of organs harvested from NSG mice treated with vehicle or ziftomenib at two different dose levels showed increased leukemic cell burden (arrows) in livers of vehicle-treated mice but no microscopic evidence of toxicity to liver, heart, kidney or guts.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Gene set enrichment scores for pathways that are down-regulated (A) vs up-regulated (B) upon ziftomenib treatment in T-ALL3.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Gene set enrichment scores for pathways that are down-regulated (A) vs up-regulated (B) upon ziftomenib treatment in T-ALL3.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Tables showing death percentage of T-ALL primary cells treated with combinations of ziftomenib and temuterkib (ERK inhibitor) or JNJ-7706621 (CDK1/2 inhibitor). (B) Synergy plot of T-ALL primary cells treated with ziftomenib and temuterkib.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Tables showing death percentage of T-ALL primary cells treated with combinations of ziftomenib and temuterkib (ERK inhibitor) or JNJ-7706621 (CDK1/2 inhibitor). (B) Synergy plot of T-ALL primary cells treated with ziftomenib and temuterkib.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
HSA synergy plots of T-ALL primary cells treated with ziftomenib (A, C) or revumenib (B) and ERK or CDK inhibitors.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
HSA synergy plots of T-ALL primary cells treated with ziftomenib (A, C) or revumenib (B) and ERK or CDK inhibitors.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease. HOXAhigh T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effective in T-ALL, but biomarkers of response remain undefined. This study aims to evaluate the efficacy of menin inhibition in T-ALL and identify molecular predictors of sensitivity. We tested menin inhibitors (ziftomenib, revumenib, and VTP50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXAhigh and HOXAlow genotypes. In vitro sensitivity assays, xenograft mouse models, transcriptomics, proteomics, and phosphoproteomics were used to characterize drug response. MEF2C modulation experiments and combination studies with cyclin-dependent kinase (CDK) 1/2 and ERK1/2 inhibitors were performed in vitro and in vivo. Menin inhibitors suppressed leukemic growth in a subset of HOXAhigh and HOXAlow primary human T-ALL samples. Similarly, ziftomenib was effective in reducing tumor burden in xenografts without major toxicity. Upon treatment, we observed downregulation of canonical menin targets (HOXA, MEIS1, and MEF2C) and upregulation of T-cell differentiation programs. Phosphoproteomic studies identified MEF2C S222 phosphorylation—mediated by CDK1/2 and ERK1/2—as a predictor of ziftomenib sensitivity in T-ALL. MEF2C overexpression promoted proliferation and ziftomenib resistance, whereas its knockdown impaired growth. Ziftomenib synergized with CDK1/2 and ERK1/2 inhibitors in vitro and improved survival in xenografted mice. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in R/R T-ALL.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
T-lineage acute lymphoblastic leukemia (T-ALL) lacks effective targeted therapies, with poor outcomes in relapsed/refractory (R/R) disease. HOXAhigh T-ALL is biologically aggressive and often resistant to standard therapy. Menin inhibitors, recently approved for KMT2A-rearranged leukemias, may be effective in T-ALL, but biomarkers of response remain undefined. This study aims to evaluate the efficacy of menin inhibition in T-ALL and identify molecular predictors of sensitivity. We tested menin inhibitors (ziftomenib, revumenib, and VTP50469) in 14 primary T-ALL samples and 8 cell lines, representing HOXAhigh and HOXAlow genotypes. In vitro sensitivity assays, xenograft mouse models, transcriptomics, proteomics, and phosphoproteomics were used to characterize drug response. MEF2C modulation experiments and combination studies with cyclin-dependent kinase (CDK) 1/2 and ERK1/2 inhibitors were performed in vitro and in vivo. Menin inhibitors suppressed leukemic growth in a subset of HOXAhigh and HOXAlow primary human T-ALL samples. Similarly, ziftomenib was effective in reducing tumor burden in xenografts without major toxicity. Upon treatment, we observed downregulation of canonical menin targets (HOXA, MEIS1, and MEF2C) and upregulation of T-cell differentiation programs. Phosphoproteomic studies identified MEF2C S222 phosphorylation—mediated by CDK1/2 and ERK1/2—as a predictor of ziftomenib sensitivity in T-ALL. MEF2C overexpression promoted proliferation and ziftomenib resistance, whereas its knockdown impaired growth. Ziftomenib synergized with CDK1/2 and ERK1/2 inhibitors in vitro and improved survival in xenografted mice. In conclusion, a subset of T-ALL, defined by high p-MEF2C S222, is sensitive to menin inhibition. Combining ziftomenib with CDK or ERK inhibition offers synergistic efficacy, supporting biomarker-driven clinical trials of this strategy in R/R T-ALL.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Chemical structures of compounds used in this work.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
Chemical structures of compounds used in this work.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Immunoblots confirming MEF2C overexpression in MOLT4 cells. (B) Eight-day growth curves for control vs MEF2C OE MOLT4 cells. (C) Co-treatment with ziftomenib (0.3 µM) and CDK1/2 inhibitor (0.3 µM) in control vs MEF2C OE MOLT4 cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
(A) Immunoblots confirming MEF2C overexpression in MOLT4 cells. (B) Eight-day growth curves for control vs MEF2C OE MOLT4 cells. (C) Co-treatment with ziftomenib (0.3 µM) and CDK1/2 inhibitor (0.3 µM) in control vs MEF2C OE MOLT4 cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia